Research programme: recombinant fibrinolysin - Grifols

Drug Profile

Research programme: recombinant fibrinolysin - Grifols

Alternative Names: Delta (K2-K5) plasmin; rPlasmin; TAL 6003

Latest Information Update: 12 Jun 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Grifols
  • Developer Bausch & Lomb; Grifols
  • Class Serine endopeptidases; Thrombolytics
  • Mechanism of Action Fibrinolysis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Stroke
  • No development reported Thrombosis
  • Discontinued Eye disorders

Most Recent Events

  • 14 Jun 2012 Preclinical development is ongoing in USA for transient ischaemic stroke
  • 14 Jun 2012 No development reported - Preclinical for Thrombosis in USA (Parenteral)
  • 03 Jun 2011 Grifols acquires Talecris Biotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top